Affiliations 

  • 1 Al-Rashed Allergy Centre, Kuwait, State of Kuwait
  • 2 Rhinology and Endoscopic Skull Base Surgery Division, Otolaryngology - Head and Neck Surgery Department, King Saud University, Riyadh, Saudi Arabia
  • 3 Awali Hospital, Manama, Bahrain
  • 4 Al Nahda Hospital, MoH, Muscat, Oman
  • 5 Royal Hospital, MoH, Muscat, Oman
  • 6 Sultan Qaboos, University Hospital, Muscat, Oman
  • 7 Al Kuwait Hospital, MoH, Dubai, United Arab Emirates
  • 8 Sulaiman Al Habib Hospital, Dubai, United Arab Emirates
  • 9 Department Otolaryngology, Head and Neck Surgery, Zain and Al Sabah Hospitals, Medical Department, Dasman Diabetes Institute, Kuwait, State of Kuwait
  • 10 Cleveland Clinic, Abu Dhabi, United Arab Emirates
  • 11 Umm Al Qura University, Makkah and KFSH&RC, Jeddah, Saudi Arabia
  • 12 Dubai HealthCare City, Dubai, United Arab Emirates
J Asthma Allergy, 2022;15:1-12.
PMID: 35018101 DOI: 10.2147/JAA.S321017

Abstract

Chronic rhinosinusitis (CRS) is defined as the inflammation of nose and paranasal sinuses, affecting the patients' quality of life and productivity. Chronic rhinosinusitis with nasal polyps (CRSwNP) is a principal clinical entity confirmed by the existence of chronic sinonasal inflammation and is characterized by anterior or posterior rhinorrhea, nasal congestion, hyposmia and/or facial pressure or facial pain. Several epidemiologic studies have revealed wide variations in the incidence of CRS among regions globally ranging from 4.6% to 12%. The Gulf countries are also witnessing an unprecedented burden of CRSwNP. According to the current clinical guidelines, glucocorticosteroids and antibiotics are the principal pharmacotherapeutic approaches. Endoscopic sinus surgery is recommended for those who have failed maximal pharmacotherapy. Recently, biologics are considered as an alternative best approach due to the complications associated with medical therapy and surgery. However, precise data on the clinical position of biologic agents in the management of CRSwNP in the Gulf region is not available. The present review article addresses the current diagnostic and management approaches for CRSwNP and also emphasizes the role of emerging biologics in the current treatment strategies for CRSwNP in the Gulf region. Further, a consensus protocol was convened to rationalize the guideline recommendations, strategize the best practices with biologics, and develop clinical practice guidelines for all primary-care specialists in the Gulf region. The consensus-based report will be a useful reference tool for primary-care physicians in primary-healthcare settings, regarding the appropriate time for the initiation of biological treatment in the Gulf region.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.